Aetna to remain in all current exchanges in 2017, teases expansion

Aetna won’t join insurers like UnitedHealth and Humana in leaving the Affordable Care Act’s health insurance marketplaces—and may expand into new states, according to the Wall Street Journal.

The company currently offers plans on 15 ACA state exchanges, and Aetna spokesman T.J. Crawford told the WSJ it has submitted rate proposals for 2017 with “no plans at this point to withdraw from any of those states.”

Crawford went on to say Aetna’s filings with regulators “preserved our options to enter certain new geographies pending careful evaluation of marketplace conditions.” While the WSJ quoted an Oklahoma regulator who claims he had been informed Aetna would begin selling exchange plans there in 2017, Crawford said the company hasn’t made any final decisions on expansion and won’t do so until September.

The announcement followed positive statements about the marketplaces by Aetna CEO Mark Bertolini, who in April called the exchanges a “good investment” based on how much it would’ve cost the company to find the same number of new customers without the Affordable Care Act. In its first quarter earnings report, Aetna said its signed up more than 900,000 people for individual coverage through the marketplaces.

Aetna’s exchange expansion plans remain separate from Humana while their merger awaits approval from regulators, as Aetna will still offer plans in Virginia, one of the four states Humana is exiting in 2017. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.